Umsetzungen mit 1‐Nitro‐2‐dimethylamino‐äthylen, V
摘要:
AbstractDie aus Methyl‐aryl‐ketonen mit 1‐Nitro‐2‐dimethylamino‐äthylen (2) darstellbaren aci‐Nitro‐acyl‐propene lassen sich zu Nitrobutadienen (3 → 8), Pyrrolen (11 → 13), Oxazinonen bzw. Chloroximen (14 → 15, 16 → 18) und über O‐Methyl‐aci‐nitro‐Verbindungen zu ungesättigten Oximinoketonen (4 → 6 → 5) umsetzen. Aus Aceton und Cyclopentanon sind mit 2 die Bis‐aci‐nitro‐äthyliden‐Derivate (24 und 26) darstellbar.
Reported herein is a visible‐light‐mediated radical approach to the α‐alkylation of ketones. This method exploits the ability of a nucleophilic organocatalyst to generate radicals upon SN2‐based activation of alkyl halides and blue light irradiation. The resulting open‐shell intermediates are then intercepted by weakly nucleophilic silyl enol ethers, which would be unable to directly attack the alkyl
The invention relates to the use of lornoxicam or analogues thereof which inhibit cyclo-oxygenase 1 and cyclo-oxygenase 2 (COX 1 and COX 2), cannot penetrate the blood-brain barrier under physiological conditions, and reduce the prostaglandin E2-induced induction of the amyloid-precursor-protein (APP), for producing a pharmaceutical composition for the treatment or prevention of Alzheimer's disease or arteriosclerosis.